Roche(US:RHHBY) Cai Jing Wang·2025-10-24 06:08Core Insights - Roche reported a total sales of 45.9 billion Swiss francs for the first nine months of 2025, representing a year-on-year growth of 7% [1] - The pharmaceutical division generated sales of 35.6 billion Swiss francs, up 9% year-on-year, while the diagnostics division achieved sales of 10.3 billion Swiss francs, with a growth of 1% [1] - Based on the performance in the first nine months, Roche raised its full-year guidance for 2025, projecting sales growth in the mid-single digits (CER) and Core EPS growth in the high single digits to low double digits [1] Product Development - Roche plans to decide or initiate Phase III clinical trials for ten new molecules this year [1] - The HER2 TKI is set to enter Phase III for HER2+ breast cancer, while Cevostamab has already entered Phase III for relapsed/refractory multiple myeloma (R/R MM) [1]